Presentation is loading. Please wait.

Presentation is loading. Please wait.

Chapter 13 Respiratory Bacilli.

Similar presentations

Presentation on theme: "Chapter 13 Respiratory Bacilli."— Presentation transcript:

1 Chapter 13 Respiratory Bacilli

2 M. tuberculosis (结核分枝杆菌)
C. diphtheria (白喉棒状杆菌) L. pneumophila(嗜肺军团菌) B .pretussis (百日咳鲍特菌) H. influenzae(流感嗜血杆菌) K. pneumoniae(肺炎克雷伯菌)

3 Section 1 M. tuberculosis 结核分支杆菌

4 Ziehl-Neelsen stain pink in a contrasting background

5 ??? Mycobacterium (fungus-bacterium) :
form mould-like pellicles when grow in the liquid media acid-fastness : impermeability by certain dyes and stains once stained, acid-fast bacteria will retain dyes when heated and treated with acidified organic compounds. thick, complex, lipid-rich, waxy cell walls ! ???

6 Mycobacterium tuberculosis Tubercle Bacilli

7 Characteristics large nonmotile rod-shaped bacterium
Chains of cells in smears made from in vitro-grown colonies often form distinctive serpentine cords. (cord factor) large nonmotile rod-shaped bacterium facultative intracellular parasite obligate aerobe slow generation time, hours

8 Characteristics Lowenstein-Jensen medium Middlebrook's medium
small and buff colored colonies 4-6 weeks inhibitors to keep contaminants from out-growing M.TB.

9 M.TB acid-fast bacteria(AFB)
Characteristics M.TB acid-fast bacteria(AFB) Ziehl-Neelsen stain the M.TB. smear is fixed, stained with carbolfuchsin (a pink dye) decolorized with acid-alcohol. The smear is counterstained with methylene-blue or certain other dyes.

10 Characteristics very sensitive to ultraviolet light heat-sensitive
destroyed in the process of pasteurization susceptible to alcohol, formaldehyde and glutaralddehyde resistant acid, alkalis and quaternary ammonium compounds.

11 Constituents Cell Wall Structure peptidoglycan Lipid: Mycolic acids
unique alpha-branched lipids , strong hydrophobic molecules Cord Factor Wax-D : Freund's complete adjuvant (CFA)


13 properties of lipids Constituents
Impermeability to stains and dyes Resistance to many antibiotics Resistance to killing by acidic and alkaline compounds Resistance to osmotic lysis via complement deposition Resistance to lethal oxidations and survival inside of macrophages

14 Constituents B. Proteins: D. capsule elicit the tuberculin reaction
C. Polysaccharides: uncertain D. capsule

15 Virulence Factors M.TB. has special mechanisms for cell entry
M.TB. can grow intracellularly. M.TB. interferes with the toxic effects of reactive oxygen intermediates produced in the process of phagocytosis Slow generation time. High lipid concentration in cell wall, Cord factor.

16 Tuberculosis

17 TB infection TB infection means that M.TB. is in the body but the immune system is keeping the bacteria under control. Macrophages surround the tubercle bacilli dfas form a hard shell. ( infiltration of macrophages and lymphocytes with development of granulomas) TB infection: not TB disease, NOT infectious  a positive reaction to the tuberculin skin test normal chest x-ray.

18 Tuberculosis: Infection vs Disease
TB Infection TB disease in lungs M.TB. present Tuberculin skin test positive Chest X-ray normal Chest X-ray usually reveals lesion Sputum smears and cultures negative Sputum smears and cultures positive No symptoms Symptoms such as cough, fever, weight loss Not infectious  Often infectious before treatment Not defined as a case of TB Defined as a case of TB

19 Pathogenesis 10% of infected persons with normal immune
systems develop TB at some point in life HIV strongest risk factor for development of TB if infected Risk of developing TB disease 7% to 10% each year Certain medical conditions increase risk that TB infection will progress to TB disease

20 Conditions That Increase the Risk of Progression to TB Disease
HIV infection Substance abuse Recent infection Chest radiograph findings suggestive of previous TB Diabetes mellitus Silicosis Prolonged corticosteriod therapy Other immunosuppressive therapy

21 Conditions That Increase the Risk of Progression to TB Disease (cont.)
Cancer of the head and neck Hematologic and reticuloendothelial diseases End-stage renal disease Intestinal bypass or gastrectomy Chronic malabsorption syndromes Low body weight (10% or more below the ideal)

22 Transmission of M. tuberculosis
Spread by droplet nuclei Expelled when person with infectious TB coughs, sneezes, speaks, or sings Close contacts at highest risk of becoming infected Transmission occurs from person with infectious TB disease (not latent TB infection)


24 Common Sites of TB Disease
Lungs Pleura Central nervous system Lymphatic system Genitourinary systems Bones and joints Disseminated (miliary TB)

25 Stages of the Disease Stage 1 Droplet nuclei are inhaled.

26 Stage 2 Stages of the Disease 7-21 days after M.TB. multiplies
macrophages are unactivated

27 Stage 3 Stages of the Disease lymphocytes infiltrate:
MHC molecules T-cell activation liberate cytokines (IFN) activation of macrophages tuberculin-positive : the result of the host developing a vigorous cell mediated immune (CMI) response

28 Stage 3 Stages of the Disease tubercle formation begins
The center of the tubercle is characterized by "caseation necrosis" meaning semi-solid or "cheesy" consistency. M.TB. cannot multiply within these tubercles because of the low pH and anoxic environment. M.TB. can persist within these tubercles for extended periods

29 Stages of the Disease Stage 4
M.TB replicate in unactivated macrophages the growing tubercle invade bronchus or blood supply line. hematogenous spread result in extrapulmonary tuberculosis otherwise known as miliary tuberculosis. at almost any anatomical location

30 Stages of the Disease Stage 4
two types 1.Exudative lesions result from the accumulation of PMN's around M.TB. bacteria replicate with virtually no resistance. This situation gives rise to the formation of a "soft tubercle". 2.Productive or granulomatous lesions hypersensitive to tuberculoproteins. This situation gives rise to the formation of a "hard tubercle".

31 Stages of the Disease Stage 5
the caseous centers of the tubercles liquify. M.TB begins to rapidly multiply extracellularly large antigen load causes the walls of nearby bronchi to become necrotic and rupture. cavity formation. M.TB. to spill into other airways and rapidly spread to other parts of the lung.

32 Classification System for TB
Type Description No TB exposure Not infected No history of exposure Negative reaction to tuberculin skin test TB exposure No evidence of infection History of exposure Negative reaction to tuberculin skin test 1 TB infection No disease Positive reaction to tuberculin skin test Negative bacteriologic studies (if done) No clinical, bacteriological, or radiographic evidence of active TB 2 TB, clinically active M. tuberculosis cultured (if done) Clinical, bacteriological, or radiographic evidence of current disease 3 TB Not clinically active History of episode(s) of TB or Abnormal but stable radiographic findings Positive reaction to the tuberculin skin test Negative bacteriologic studies (if done) and No clinical or radiographic evidence of current disease 4 5 TB suspected Diagnosis pending

33 Drug-Resistant TB Drug-resistant TB transmitted same way as
drug-susceptible TB Drug resistance is divided into two types: Primary resistance develops in persons initially infected with resistant organisms Secondary resistance (acquired resistance) develops during TB therapy

34 TB Disease and Infection
Testing for TB Disease and Infection

35 Purpose of Targeted Testing
Find persons with LTBI who would benefit from treatment Find persons with TB disease who would benefit from treatment Groups that are not high risk for TB should not be tested routinely

36 All testing activities should be accompanied
by a plan for follow-up care.

37 the Tuberculin Skin Test or Mantoux test
Administering the Tuberculin Skin Test or Mantoux test Inject intradermally 0.1 ml of 5TU(0.000lmg) PPD tuberculin PPD(purified protein derivative) Produce wheal 6 mm to 10 mm in diameter Do not recap, bend, or break needles, or remove needles from syringes Follow universal precautions for infection control


39 Reading the Tuberculin Skin Test
Read reaction hours after injection Measure only induration Record reaction in millimeters


41 Tuberulin Test positive if the diameter of the resulting lesion is 5 mm or greater. The lesion is characterized by erythema (redness) and swelling and induration (raised and hard).

42 Classifying the Tuberculin Reaction
>=5 mm is classified as positive in HIV-positive persons Recent contacts of TB case Persons with fibrotic changes on chest radiograph consistent with old healed TB Patients with organ transplants and other immunosuppressed patients

43 Classifying the Tuberculin Reaction (cont.)
>=10 mm is classified as positive in Recent arrivals from high-prevalence countries Injection drug users Residents and employees of high-risk congregate settings Mycobacteriology laboratory personnel Persons with clinical conditions that place them at high risk Children <4 years of age, or children and adolescents exposed to adults in high-risk categories

44 Classifying the Tuberculin
Reaction (cont.) >=15 mm is classified as positive in Persons with no known risk factors for TB Targeted skin testing programs should only be conducted among high-risk groups

45 Factors that May Affect the
Skin Test Reaction Type of Reaction Possible Cause False-positive Nontuberculous mycobacteria BCG vaccination Anergy False-negative Recent TB infection Very young age (< 6 months) Live-virus vaccination Overwhelming TB disease

46 Anergy Do not rule out diagnosis based on negative skin test result
Consider anergy in persons with no reaction if HIV infected Overwhelming TB disease Severe or febrile illness Viral infections Live-virus vaccinations Immunosuppressive therapy. Anergy skin testing no longer routinely recommended

47 Boosting Some people with LTBI may have negative skin
test reaction when tested years after infection Initial skin test may stimulate (boost) ability to react to tuberculin Positive reactions to subsequent tests may be misinterpreted as a new infection

48 Two-Step Testing Use two-step testing for initial skin testing of adults who will be retested periodically If first test positive, consider the person infected If first test negative, give second test 1-3 weeks later If second test positive, consider person infected If second test negative, consider person uninfected

49 Diagnosis of TB

50 Evaluation for TB Medical history Physical examination
Mantoux tuberculin skin test Chest radiograph Bacteriologic or histologic exam

51 Symptoms of Pulmonary TB
Productive, prolonged cough (duration of >=3 weeks) Chest pain Hemoptysis

52 Systemic Symptoms of TB
Fever Chills Night sweats Appetite loss Weight loss Easy fatigability

53 Medical History Symptoms of disease
History of TB exposure, infection, or disease Past TB treatment Demographic risk factors for TB Medical conditions that increase risk for TB disease

54 Mantoux Tuberculin Skin Test
Preferred method of testing for TB infection in adults and children

55 Chest Radiograph Abnormalities often seen in apical
or posterior segments of upper lobe or superior segments of lower lobe May have unusual appearance in HIV-positive persons Cannot confirm diagnosis of TB Arrow points to cavity in patient's right upper lobe.

56 Specimen Collection Obtain 3 sputum specimens for smear
examination and culture Persons unable to cough up sputum, induce sputum, bronchoscopy or gastric aspiration Follow infection control precautions during specimen collection

57 Smear Examination Strongly consider TB in patients with smears
containing acid-fast bacilli (AFB) Results should be available within 24 hours of specimen collection Presumptive diagnosis of TB

58 Smear Examination sputum sample is treated  with NaOH to kill other contaminating bacteria detection of acid-fast bacilli in sputum via the Ziehl-Neelsen method

59 Lowenstein-Jensen medium
culture Use to confirm diagnosis of TB Culture all specimens, even if smear negative Lowenstein-Jensen medium 4-6 weeks NEW: BACTEC System 9-16days

60 Drug Susceptibility Testing
Drug susceptibility testing on initial M. tuberculosis isolate Repeat for patients who Do not respond to therapy Have positive cultures despite 2 months of therapy Promptly forward results to the health department

61 Treatment multiple drugs usually lasts from 6-9 months. rifampin (RIF)
isoniazid (INH), pyrazinamide (PZA ) ethambutol (EMB) streptomycin (SM)

62 Basic Principles of Treatment
Provide safest, most effective therapy in shortest time Multiple drugs to which the organisms are susceptible Never add single drug to failing regimen Ensure adherence to therapy

63 Adherence Nonadherence is a major problem in TB control
Use case management and directly observed therapy (DOT) to ensure patients complete treatment

64 Infection Control in Health Care Settings

65 Infectiousness Patients should be considered infectious if they
Are coughing Are undergoing cough-inducing or aerosol-generating procedures, or Have sputum smears positive for acid-fast bacilli and they Are not receiving therapy Have just started therapy, or Have poor clinical response to therapy

66 Infectiousness (cont.)
Patients no longer considered infectious if they meet all of these criteria: Are on adequate therapy Have had a significant clinical response to therapy, and Have had 3 consecutive negative sputum smear results

67 Prevention vaccine against M.TB. :
BCG (Bacillus of Calmette and Guerin) BCG consists of a live attenuated strain derived from Mycobacterium bovis. This strain of Mycobacterium has remained avirulent for over 60 years.

68 BCG Vaccination

69 Recommendations for BCG Vaccination
recommended in immunization programs or TB control programs in China

70 BCG Contraindications
Contraindicated in persons with impaired immune response from HIV infection Congenital immunodeficiency Leukemia Lymphoma Generalized malignancy Receiving high-dose steroid therapy Receiving alkylating agents Receiving antimetabolites Receiving radiation therapy

71 Tuberculin Skin Testing
BCG Vaccination and Tuberculin Skin Testing Tuberculin skin testing not contraindicated for BCG-vaccinated persons LTBI diagnosis and treatment for LTBI considered for any BCG-vaccinated person whose skin test reaction is >=10 mm, if any of these circumstances are present: Was contact of another person with infectious TB Was born or has resided in a high TB prevalence country Is continually exposed to populations where TB prevalence is high

72 leprosy (Hansen's Disease)
Mycobacterium leprae leprosy (Hansen's Disease)

73 leprosy (Hansen's Disease)
Infect skin, nerves chronic disease disfigurement "tuberculoid" leprosy & "lepromatous" leprosy

74 diagnosis The organism does not grow in culture media
it grow at low temperature it grows well in the armadillo acid-fast stains of skin biopsies and clinical picture Lepromin is used in skin testing.  (but no value for diagnosis)

75 Treatment Treatment with antibiotics (initially dapsone and now multi-drug) is effective and the overall disease incidence worldwide is down.

76 Gram-positive, aerobic, nonmotile, Rod-shaped
Corynebacteria Gram-positive, aerobic, nonmotile, Rod-shaped

77 "Chinese-letter" arrangement of cells : club-shaped or V-shaped
"barred" appearance : polyphosphate inclusions called metachromatic granules(Babes-Ernst bodies )

78 Corynebacterium Diphtheriae
a thick gray coating over back of throat. pseudomembrane This coating can eventually expand down through airway and, if not treated, the child could die from suffocation 

79 Pathogenicity Invasion Toxigenesis:
The diphtheria toxin causes the death eukaryotic cells and tissues by inhibition protein synthesis in the cells


81 Diphtheria Toxin Production
Following lysogenic conversion with corynebacteriophage ß, or closely related corynebacteriophages, nontoxigenic strains of C diphtheriae become toxigenic

82 Diagnosis staining for metachromatic bodies : intracellular polyphosphate granules (pink) compared to the rest of the cell (blue) Characteristic black colonies are seen on tellurite agar Production of exotoxin can be determined by in vivo or in vitro tests.

83 Treatment & Prevention
toxin-neutralizing antibody (antitoxin) antibiotics toxoid a trivalent vaccine containing diphtheria toxoid, pertussis vaccine, and tetanus toxoid (DPT or DTP vaccine).

Download ppt "Chapter 13 Respiratory Bacilli."

Similar presentations

Ads by Google